VC  Remeditex Ventures

http://remeditex.com





     Office Locations:

2101 Cedar Springs, Suite 601
Dallas, TX 75201
Phone: 214-506-2662

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Remeditex Ventures' mission is to develop early stage biomedical science and make Texas a preferred location for biotechnology companies, venture capitalists, and entrepreneurs. The objectives of Remeditex are to: Accelerate the pace of commercialization of biomedical research in Texas; Help create and support a thriving biotechnology industry in Texas; Attract biotech venture capital to Texas; and Achieve significant returns to support the next generation of promising science. Remeditex is looking to partner with the universities and health systems in Texas diligently performing world-class research to gain a better understanding of the mechanisms of disease and more effective diagnostics, therapeutics, or prevention strategies. The firm is interested in translational research projects with highly defensible intellectual property and focused on diseases with significant unmet clinical needs and on potentially disruptive technologies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Brett Ringle President
    Claire Aldridge PhD Vice President
    Dennis Stone MD Chief Scientific Officer
    John Creecy Chief Executive Officer
    John Elwood Vice President

     

    Portfolio companies include:


      Apollo Endosurgery
        web link


      Bellicum Pharmaceuticals
        web link


      BiO2 Medical
        web link


      Bioptix
        web link


      miRagen
        web link


      Navitor Pharmaceuticals
        web link


      Peloton Therapeutics
        web link


      Quartet Medicine
        web link


      Rodin
        web link


      Tigercat Pharma
        web link


      VuComp
        web link


     

    Recent News:


      There is no recent news for Remeditex Ventures.